Synagis, illustration of pre-filled syringe form (not a photo of the actual pack)

Illustrative image.

Synagis

Palivizumab

Prescription required

$731.00

0.5ml · 1

BrandBranded medicine· By Abbvie

Strength

Choose a pack

  • Selected pack

Packs in this delivery

1

Test mode: no payment is taken. View cart

Ships cold, in insulated packing

This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

50mg/0.5ml

50mg

100mg

100mg/ml

0.5ml

About Synagis

Overview

Synagis (palivizumab) is a monoclonal antibody medicine used to prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in certain infants and young children. Eligible children include those born at or before 35 weeks of pregnancy who are 6 months or younger at the start of RSV season, and those 24 months or younger with bronchopulmonary dysplasia requiring medical treatment in the previous 6 months or congenital heart disease that significantly affects blood flow. It works by targeting the RSV F protein to inhibit the virus. Its safety and effectiveness for treating RSV disease have not been established.

What it treats

Synagis (palivizumab) is used to prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children who, at the start of RSV season: - Are 6 months old or younger and were born at or before 35 weeks of pregnancy. - Are 24 months old or younger and have bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months. - Are 24 months old or younger and have congenital heart disease that significantly affects blood flow. Its safety and effectiveness for treating RSV disease have not been established.

Safety information

Side effects

Common side effects include fever and rash. Serious reactions include anaphylaxis, anaphylactic shock and other severe, sudden allergic reactions. Fatal cases have been reported. Seek emergency medical help if a severe allergic reaction occurs. Synagis must be permanently stopped if such a reaction occurs.

When to call your doctor

- Seek emergency medical help immediately if your child has a severe allergic reaction (anaphylaxis), which can be life-threatening.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Synagis must not be given to children who have previously had a significant allergic reaction to it. Severe allergic reactions, including anaphylaxis and anaphylactic shock, have been reported, including fatal cases. If a severe allergic reaction occurs, Synagis must be permanently stopped and appropriate treatment given. Use caution in children with low platelet counts (thrombocytopenia) or any blood-clotting disorder because Synagis is injected into a muscle. Palivizumab may interfere with some RSV diagnostic tests, including certain antigen detection tests. Safety and effectiveness have not been established in children older than 24 months when treatment begins.

Interactions

No formal drug interaction studies have been conducted with Synagis. In one clinical trial, no additional increase in adverse reactions was observed in children receiving routine childhood vaccines, influenza vaccine, bronchodilators or corticosteroids alongside Synagis.

Using Synagis

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton to protect it from light. Check the pack for whether it must be refrigerated before first use. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label SYNAGIS (PALIVIZUMAB) INJECTION, SOLUTION [SWEDISH ORPHAN BIOVITRUM AB (PUBL)] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines